(Note: This is NOT a traditional IPO. IPOScoop has NO CALL on this offering because it is a NASDAQ uplisting from the AIM, which is operated by the London Stock Exchange. The last reported sale price of our common stock on July 23, 2021, was 10 British pounds sterling per share, or about US$13.79 per share, based on the noon buying rate for British pounds sterling of 1 British pound sterling equals $1.3785 on July 16, 2021. The listing on our IPOScoop IPO Calendar is only a professional courtesy.)
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past twenty years, we have developed and commercialized our proprietary Flow Electroporation platform, which facilitates complex engineering of a wide variety of cells. Electroporation is a method of transfection, or the process of deliberately introducing molecules into cells, that involves applying an electric field in order to temporarily increase the permeability of the cell membrane. This precisely controlled increase in permeability allows the intracellular delivery of molecules, such as genetic material and proteins, that would not normally be able to cross the cell membrane as easily.
Our ExPERT technology platform is being used in the clinic to support the development of next-generation cell therapy approaches to treat human disease.
We have entered into 13 Strategic Platform Licenses with commercial cell therapy developers, which include: CRISPR/Casebia Therapeutics; CRISPR Therapeutics; Kite Pharma (now Gilead); Precision Biosciences; Editas Medicine; VOR Biopharma; KSQ; Allogene Therapeutics; Caribou Biosciences; Apeiron Biologics; Celularity; and Myeloid Therapeutics.
|Industry:||Services - Commercial Physical & Biological Research|
|Address||22 Firstfield Road, Suite 110 Gaithersburg, Maryland 20878|
|Phone Number||(301) 944-1700|
|View Prospectus:||MaxCyte, Inc|
|Revenues||$26.92 mil (last 12 months)|
|Net Income||$-15.87 mil (last 12 months)|
|Price range||$13.00 - $13.00|
|Est. $ Volume||$175.5 mil|
|Manager / Joint Managers||Cowen and Company/ Stifel/ William Blair|
|CO-Managers||BTIG/ Stephens, Inc.|
|Expected To Trade:||7/30/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|